Aclaris Therapeutics Inc. (ACRS)’s Financial Results Comparing With Alpine Immune Sciences Inc. (NASDAQ:ALPN)

This is therefore a contrasting of the dividends, analyst recommendations, profitability, risk, earnings and valuation, institutional ownership in Aclaris Therapeutics Inc. (NASDAQ:ACRS) and Alpine Immune Sciences Inc. (NASDAQ:ALPN). The two are both Biotechnology companies that compete with one another.

Earnings & Valuation

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Aclaris Therapeutics Inc. 14.01M 16.88 140.07M -3.85 0.00
Alpine Immune Sciences Inc. N/A 260.47 43.56M -2.15 0.00

Table 1 showcases the top-line revenue, earnings per share and valuation of Aclaris Therapeutics Inc. and Alpine Immune Sciences Inc.


Table 2 provides Aclaris Therapeutics Inc. and Alpine Immune Sciences Inc.’s return on assets, net margins and return on equity.

Net Margins Return on Equity Return on Assets
Aclaris Therapeutics Inc. -999.79% -62.8% -55.6%
Alpine Immune Sciences Inc. 0.00% -43.3% -39.1%

Volatility and Risk

Aclaris Therapeutics Inc. is 22.00% more volatile than Standard and Poor’s 500 due to its 1.22 beta. Competitively, Alpine Immune Sciences Inc.’s 113.00% volatility makes it more volatile than Standard and Poor’s 500, because of the 2.13 beta.


Aclaris Therapeutics Inc. has a Current Ratio of 6.5 and a Quick Ratio of 6.5. Competitively, Alpine Immune Sciences Inc.’s Current Ratio is 9.2 and has 9.2 Quick Ratio. Alpine Immune Sciences Inc.’s better ability to pay short and long-term obligations than Aclaris Therapeutics Inc.

Insider & Institutional Ownership

Roughly 96.8% of Aclaris Therapeutics Inc. shares are held by institutional investors while 53% of Alpine Immune Sciences Inc. are owned by institutional investors. Aclaris Therapeutics Inc.’s share held by insiders are 4.3%. On the other hand, insiders held about 0.2% of Alpine Immune Sciences Inc.’s shares.


In this table we show the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.

Performance (W) Performance (M) Performance (Q) Performance (HY) Performance (Y) Performance (YTD)
Aclaris Therapeutics Inc. 3.65% -2.3% -21.72% -56.54% -65.15% -7.85%
Alpine Immune Sciences Inc. 6.11% 8.59% 43.6% 9.79% -21.65% 88.86%

For the past year Aclaris Therapeutics Inc. has -7.85% weaker performance while Alpine Immune Sciences Inc. has 88.86% stronger performance.


Alpine Immune Sciences Inc. beats Aclaris Therapeutics Inc. on 8 of the 9 factors.

Aclaris Therapeutics, Inc., a clinical-stage biotechnology company, focuses on identifying, developing, and commercializing topical drugs to address various unmet needs in dermatology. Its lead drug candidate is A-101, a hydrogen peroxide topical solution, which is in Phase III clinical trials for the treatment of seborrheic keratosis (SK), a common non-malignant skin tumor. The company is also developing A-101 as a prescription treatment for common warts. In addition, it is developing JAK inhibitors, including ATI-50001 that has completed Phase I clinical trial for the oral treatment of alopecia totalis and alopecia universalis; and ATI-50002, which has completed Phase I clinical trial for the topical treatment of patchy autoimmune dermatologic condition. Aclaris Therapeutics, Inc. was founded in 2012 and is headquartered in Malvern, Pennsylvania.

Alpine Immune Sciences, Inc. focuses on the discovery and development of protein-based immunotherapies for the treatment of cancer, inflammatory disorders, and other diseases. Its lead programs include ALPN-101, an ICOS/CD28 antagonist program for the treatment of autoimmune and inflammatory diseases; and ALPN-202 program for the treatment of cancer. The company has a collaboration and licensing agreement with the Kite Pharma, Inc. for discovering and developing protein-based immunotherapies targeting the immune synapse to treat cancer. Alpine Immune Sciences, Inc. is headquartered in Seattle, Washington.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.